Company intelligence / Profile preview
Vanqua Bio
- Ownership
- Public · N/A
- Employees
- ~75
- Development stage
- Preclinical
Overview
Vanqua Bio has advanced its lead candidate VQ‑101, a brain‑penetrant small molecule allosteric activator of glucocerebrosidase, into clinical development for Parkinson’s disease. The company leverages a proprietary patient-derived iPSC platform to identify novel therapies targeting lysosomal dysfunction and innate immune overactivation. Early results indicate promise in modulating key neurodegenerative pathways; the lead asset entered Phase Ib trials in late 2024.[3][6]
- Therapeutic areas
- Rare DiseasesNeurology
- Modalities
- Small molecules (notably allosteric activators of GCase)[3][9]Potentially others in early discovery for immune modulation[9]
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Vanqua Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vanqua Bio.